Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2020 | Targeted therapy for MDS

Drorit Merkel • 5 Mar 2020
MDS 2020
Anemias Myelodysplastic Syndromes Azacitidine Lenalidomide Luspatercept Venetoclax

Drorit Merkel, MD, Cancer Biology Research Center, Tel Aviv University, Tel Aviv, Israel, outlines the importance of comprehending the genetic changes in high-risk myelodysplastic syndromes (MDS) to allow the development of targeted therapies. Also, Dr Merkel discusses current and upcoming treatment options for low and high-risk patients. This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.

More from Drorit Merkel

1:25
Prognosis and treatment in high-risk MDS
Drorit Merkel • 5 Mar 2020
2:17
The etiology and epidemiology of myelodysplastic syndromes
Drorit Merkel • 6 Mar 2020
1:44
Utilizing chromosome banding in MDS
Drorit Merkel • 6 Mar 2020

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
3:45
A 2-year analysis of the EBMT-SAAWP RACE trial: eltrombopag in aplastic anemia
Antonio Risitano • 16 Apr 2024
3:19
Key clinical trials in MDS taking place in the US
Guillermo Garcia-Manero • 9 Apr 2024
1:34
Sequencing of agents in LR-MDS
Guillermo Garcia-Manero • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals